New number of shares and votes in Medivir AB (publ)

The number of shares and votes in Medivir AB (publ) (the “Company”) increased during December 2025 as a result of the rights issue resolved by the board of directors on 8 October 2025, and approved by the extraordinary general meeting on 10 November 2025.

As of 30 December 2025, the total number of shares in the Company amounts to 451,121,383 shares, of which 448,671,220 ordinary shares and 2,450,163 class C shares (previously 114,617,968 shares, of which 112,167,805 ordinary shares and 2,450,163 class C shares). All shares in the Company carry 448,916,236 votes. One ordinary share entitles the holder to one (1) vote, and one class C share entitles the holder to one tenth (1/10) of a vote. All class C shares are held by the Company.
 
As of 30 December 2025, the share capital amounts to SEK 67,668,207.45 (previously SEK 17,192,695.20[1]).

 The English text is an unofficial translation of the original Swedish text. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.

For additional information, please contact;
Jens Lindberg
Chief Executive Officer
Medivir AB
M: [phone]
Email: [e-mail]
 
Magnus Christensen
Chief Financial Officer
Medivir AB
M: [phone]
Email: [e-mail]

About Medivir
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is focusing on the development of fostroxacitabine bralpamide (fostrox), a drug candidate designed to selectively treat cancer cells in the liver and to minimize side effects. Collaborations and partnerships are important parts of Medivir’s business model, and the drug development is conducted either by Medivir or in partnership. Medivir’s share (ticker: MVIR) is listed on Nasdaq Stockholm’s Small Cap list. www.medivir.com. 

[1] At the Extraordinary General Meeting on 10 November 2025, it was resolved to reduce the Company's share capital by SEK 40,116,288.80. After the reduction of the share capital, which was registered with the Swedish Companies Registration Office in December 2025, the Company's share capital amounted to SEK 17,192,695.20.

This information is information that Medivir is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-12-30 08:30 CET.

Attachments
Press Release (PDF)